ZACKS·2025-04-28 16:30Core Insights - D-Wave Quantum Inc. (QBTS) and Accenture (ACN) are both leveraging AI to enhance their operations and establish leadership in their respective fields [1][2] D-Wave Quantum (QBTS) - QBTS has gained significant attention for its Advantage2 prototype, which outperforms classical supercomputers in solving complex magnetic material problems [3] - The company utilizes quantum annealing to optimize neural network weights, enabling the training of more complex models across various domains, including drug discovery and material sciences [4] - Financially, QBTS reported revenues of $8.8 million in fiscal 2024, unchanged from the previous year, but bookings increased by 128%, indicating potential future revenue growth [5] - The Zacks Consensus Estimate for QBTS's 2025 sales is $23.3 million, reflecting a 100% year-over-year increase, with a projected loss of 25 cents per share [9] Accenture (ACN) - ACN's growth strategy is heavily focused on AI, with significant advancements following partnerships with OpenAI and Sanctuary AI, enhancing its capabilities in the GenAI market [6] - In fiscal 2024, ACN achieved $3 billion in GenAI-related bookings, with $1.4 billion in the second quarter of fiscal 2025, positioning itself favorably in a growing market projected to expand at a CAGR of 37.6% from 2025 to 2030 [7] - The company reported a 4% year-over-year increase in managed services revenues in fiscal 2024, with an anticipated growth of 5.7% in fiscal 2025 [8] - The Zacks Consensus Estimate for ACN's fiscal 2025 sales is $68.4 billion, indicating a 5.4% year-over-year growth, with earnings projected at $12.7 per share, a 6.3% increase [10] Valuation Comparison - Accenture is trading at a forward price-to-sales ratio of 2.6, below its 12-month median of 3.09, while D-Wave Quantum's ratio is significantly higher at 81.28X compared to its median of 13.58X [11] Investment Outlook - D-Wave Quantum is viewed as a buy due to strong bookings and top-line expectations, along with its cost-effective solutions [13] - Accenture is rated as a hold, as it operates in a mature industry with slower growth potential, suggesting investors may wait for stronger earnings catalysts before investing [13][14]